« On Islam And Human Sacrifice | Main | Iranian opposition group says it has new evidence that Iran is producing enriched uranium at a covert Defense Ministry facility in Tehran. »

November 17, 2004

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition

Topics: Clinical Pharmacology

Abstract report on topic of interest - Gastroenterology. 2004 Aug;127(2):395-402, Laine L, Maller ES, Yu C, Quan H, Simon T. University of Southern California School of Medicine, Department of Medicine, Los Angeles 90033, USA. llaine@usc.edu

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

BACKGROUND & AIMS: We assessed the risk of ulcers with low-dose aspirin and the interaction of low-dose aspirin with a COX-2 selective inhibitor in a double-blind trial that compared placebo, low-dose aspirin, rofecoxib + low-dose aspirin, and ibuprofen. METHODS: Osteoarthritis patients > or =50 years of age without ulcers or erosive esophagitis at baseline endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combined with aspirin 81 mg/day, or ibuprofen 800 mg 3 times a day. Repeat endoscopies were performed at 6 and 12 weeks. RESULTS: The 12-week cumulative incidence of ulcers was placebo (N = 381) 5.8%, aspirin (N = 387) 7.3%, rofecoxib combined with aspirin (N = 377) 16.1%, and ibuprofen (N = 374) 17.1% (P < 0.001 for rofecoxib combined with aspirin and for ibuprofen vs. each of placebo and aspirin). Over 12 weeks, mean increases in the number of erosions were placebo 0.17, aspirin 0.85 (P = 0.002 vs. placebo), rofecoxib combined with aspirin 1.67, and ibuprofen 1.91 (both P < 0.001 vs. aspirin and placebo).  CONCLUSIONS: Low-dose aspirin alone did not significantly increase ulcer incidence. Addition of a cyclooxygenase-2 (COX-2) selective inhibitor to low-dose aspirin increased ulcer incidence, to a rate not significantly less than a nonselective nonsteroidal anti-inflammatory drug (NSAID) alone. Determining the relative impact of COX-2 selective inhibitors and nonselective NSAIDs on gastrointestinal mucosal injury in low-dose aspirin users will require further study.

Posted by Hyscience at November 17, 2004 11:19 AM

Articles Related to Clinical Pharmacology:

• Britain tests first Cannabis related medicine for rheumatoid arthritis - Nov 13, 2005
• Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma - May 26, 2005
• Cystatin C May Push Creatinine Off Risk Radar - May 19, 2005
• Cancer Treatment Success Stuns Scientists - May 16, 2005
• Antibody, cancer drug combo shows promise against breast tumors - May 16, 2005
• USC researchers determine mechanism of action of motexafin gadolinium (Xcytrin) - May 02, 2005
• Herceptin® Combined With Chemotherapy Improves Disease-Free Survival for Patients With Early-Stage Breast Cancer - Apr 26, 2005
• Selenium will have critical role in prostate cancer treatment - Fox Chase Cancer Center - Apr 21, 2005
• Traditional Medicine Derivatives Kill Cancer Cells - Apr 20, 2005
• Compound from Chinese medicine shows promise in head and neck cancer, U-M study finds - Apr 19, 2005